Eurofins: Focus Pays Off — Margin Expansion and a Core-Business Pivot

H1 2026 shows 29% EPS growth and record margins as Eurofins sharpens its portfolio and replants for BioPharma recovery

ERF.PA · Earnings Call · 2026-07-23

A Margin Story That Belies the Top Line

The headline is unmistakable: “we've had a strong H1 2026 with very strong improvement of results, 29% EPS growth.” — Gilles Martin, CEO · 2026-07-23 But the top line tells a more tempered tale. Organic growth was just 2.7% in the half, buffeted by a 2.9% FX headwind. Yet adjusted EBITDA margin reached 23.7%, up 130 basis points year-on-year — a level that had previously seemed out of reach for a product testing company still in the middle of a complex IT overhaul. CEO Gilles Martin was candid: “we are above our objectives. We are above what we were expecting in what is traditionally the lower margin part of the year.” — Gilles Martin, CEO · 2026-07-23 The margin expansion is not a fluke. It is the payoff from years of hub lab construction, site consolidations, and a relentless focus on eliminating duplicate costs. Laurent Lebras, CFO, noted that free cash flow to the firm jumped 46% to EUR 403 million, with cash conversion at a record 47%. That cash engine is now being redirected: the company announced the divestment of its electrical and electronic testing business to UL at a multiple "almost double" the company's own trading multiple, and the acquisition of Element Material Technologies' Life Science Testing Services in North America.

A Sharper Portfolio, A Clearer Focus

Martin's rationale for the portfolio moves is explicit:

focused is if you are 3 or 4x bigger than your next competitor and you are the market leader, you benefit from the scale.
Gilles Martin, CEO · 2026-07-23

The divestment and acquisition are two sides of the same coin. The electrical and electronic testing business, while good, was not core to the "testing for life" mission. UL is a better owner, and the proceeds allow Eurofins to reinvest in a business where it already has scale — Food Testing and environmental testing in North America, and BioPharma product testing. The acquired Element business will plug directly into that existing network. The timing matters. In the prior January call, Martin hinted at a similar logic: “we know what those assets are worth. ... our stock is trading at 10x. So obviously, if I have extra capital to deploy, it's a no-brainer to buy back our shares.” — Gilles Martin, CEO · 2026-01-29 The difference now is that Eurofins is using its undervalued currency as both a buyer and a seller — recycling capital out of non-core businesses and into areas where it can deploy its proprietary IT and robotics stack.

BioPharma: The Fog Begins to Lift

The softness in BioPharma has been a recurring theme, but the tone has shifted. In H1 2026, BioPharma product testing in Europe was flat, hurt by a couple of large contracts ending. Martin was at pains to frame this as lumpy, not structural: “it's not that we lost it to a competitor, but sometimes pharma has certain programs, they develop a new product or they build a new site that they need to validate.” — Gilles Martin, CEO · 2026-07-23 The company expects those contracts to be replaced, and there are early signs of life in Discovery funding. The bigger story is the margin improvement that is now being delivered even while growth is sluggish. The mature scope of the business — roughly EUR 7 billion in revenue — is already hitting 25.3% EBITDA margin, well ahead of the group's 2027 target of 24%. That gives credibility to the mid-single-digit organic growth objective for H2 and the longer-term 6.5% secular growth rate. As Martin put it: “we maintain our objective to grow a bit above mid-single digits on the secular level.” — Gilles Martin, CEO · 2026-07-23 The market has been skeptical, but the cash flow and margin trajectory suggest the focus strategy is working. If BioPharma does recover as expected — with central lab and BioAnalysis contracts starting in H2 — the combination of top-line acceleration and operating leverage could be powerful. That is the true re-rating catalyst.